Against the trend, Novartis has dramatically increased its discovery infrastructure because, unlike most of its competitors, it believes it can cut R&D attrition. Drug research fails, its R&D execs believe, because it oversimplifies heterogeneous diseases. Instead, Novartis is testing drugs early in rare diseases that might be models of broader conditions. The proof-of-concept idea isn't new, but Novartis is exploiting it more extensively than anyone else, in virtually all new programs.
By Roger Longman
Two basic yet conflicting assumptions underlie corporate pharmaceutical R&D. The first is that the odds of success are by and...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
